Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
EdiGene
About
EdiGene is a biotechnology company that develops genome editing technologies.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $67M
- Industries
- Biotechnology,Genetics,Health Care
- Founded date
- Jan 1, 2015
- Number Of Employee
- 51 - 100
- Operating Status
- Active
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 21, 2021 | Series B | ¥400M | 1 | — | — | Detail |
| Oct 13, 2020 | Series B | $67M | 1 | — | — | Detail |
| Sep 17, 2019 | Series A | ¥81.50M | 1 | — | — | Detail |
| Feb 6, 2019 | Series A | $10M | 1 | — | — | Detail |
| Aug 13, 2018 | Series A | $14.54M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lilly Asia Ventures
|
— | Series B |
